Successful commercialization of allogeneic umbilical cord blood-derived mesenchymal stem cells products
MEDIPOST has successfully launched World’s First Regulatory-Approved allogeneic umbilical cord blood-derived mesenchymal stem cells product CARTISTEM® in Korea. In addition, clinical trials for the preventive treatment in patients with bronchopulmonary dysplasia (BPD) are in progress.
First-Generation of Stem Cell Products
CARTISTEM®
Treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis(OA) without age limit.
· Biologics License Application(BLA) Market-Approval by Ministry of Food and Drug Safety(MFDS), Korea in January 2012
· Completed US FDA Phase 1/2a Clinical Trial
· Phase 3 clinical trial ongoing in Japan
PNEUMOSTEM®
Preventive Treatment for Bronchopulmonary Dysplasia(BPD)
· Phase 2 clinical trial ongoing in Korea
· Completed US FDA Phase 1/2 clinical trial
· Orphan Drug Designation by US FDA & EMA
· Fast-Track Designation by US FDA